124 related articles for article (PubMed ID: 11365860)
1. Too little of a good thing.
Friedland GH; Gulick RM
AIDS Clin Care; 1998 Oct; 10(10):76-7. PubMed ID: 11365860
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral rounds. When success is a pain.
Bartlett JG; del Rio C
AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
[No Abstract] [Full Text] [Related]
4. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
5. Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
Bartlett JA; Miralles GD; Sevin AD; Silberman M; Pruitt SK; Ottinger J; Gryszowska V; Fiscus SA; Bucy RP;
AIDS Res Hum Retroviruses; 2002 May; 18(8):535-43. PubMed ID: 12036483
[TBL] [Abstract][Full Text] [Related]
6. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.
Sension MG; Bellos NC; Johnson J; Sepulveda GE; DeJesus E; Santana JL; Ames MH; Goodwin SD
HIV Clin Trials; 2002; 3(5):361-70. PubMed ID: 12407485
[TBL] [Abstract][Full Text] [Related]
8. To AIDS and back with Norvir, D4T, 3TC and nutritional therapies. An interview with Michael Golk.
Golk M
Posit Health News; 1998; (No 16):5-7. PubMed ID: 11365018
[TBL] [Abstract][Full Text] [Related]
9. Antiretrovirals for HIV nephropathy?
Saag M; Hecht F
AIDS Clin Care; 1999 Jun; 11(6):50. PubMed ID: 11366883
[TBL] [Abstract][Full Text] [Related]
10. Simplifying drug regimens.
HIV Hotline; 1998 Mar; 8(1):11. PubMed ID: 11365353
[TBL] [Abstract][Full Text] [Related]
11. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
Roca B; Gómez CJ; Arnedo A
J Infect; 2000 Jul; 41(1):50-4. PubMed ID: 10942640
[TBL] [Abstract][Full Text] [Related]
12. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
Rockstroh JK; Altfeld M; Kupfer B; Kaiser R; Fätkenheuer G; Salzberger B; Schneweis KE; Spengler U
Eur J Med Res; 1999 Jul; 4(7):271-4. PubMed ID: 10425264
[TBL] [Abstract][Full Text] [Related]
13. Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
Yamamoto Y; Yasuoka A; Tachikawa N; Teruya K; Genka I; Yamaguchi M; Yasuoka C; Kikuchi Y; Aoki M; Oka S
Jpn J Infect Dis; 1999 Dec; 52(6):248-9. PubMed ID: 10738365
[No Abstract] [Full Text] [Related]
14. Clinical trials group: two studies are now open to patients who qualify.
Craig K
HIV Clin; 2000; 12(1):5. PubMed ID: 11810862
[No Abstract] [Full Text] [Related]
15. Some competition for 1592.
GMHC Treat Issues; 1997; 11(4/5):10-1. PubMed ID: 11364373
[TBL] [Abstract][Full Text] [Related]
16. Phase II/III Trials of Viracept start.
AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361632
[No Abstract] [Full Text] [Related]
17. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Rizzardi GP; De Boer RJ; Hoover S; Tambussi G; Chapuis A; Halkic N; Bart PA; Miller V; Staszewski S; Notermans DW; Perrin L; Fox CH; Lange JM; Lazzarin A; Pantaleo G
J Clin Invest; 2000 Mar; 105(6):777-82. PubMed ID: 10727446
[TBL] [Abstract][Full Text] [Related]
18. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
20. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]